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modeling in cost-based physician proﬁling. Here, we examine a
reﬁned modeling approach and the use of physician quality score.
METHODS: Symmetry’s Episode Treatment Groups (ETG)TM
software was employed to group 2 years of commercial claims
for 1 million members and 6,000 physicians into episodes. Our
previous method used more than 200 ETG-level Gamma regres-
sions to generate expected costs for each care episode, which
were then used to calculate the standardized cost difference
(SCD) in an effort to characterize physician practice efﬁciency. In
this approach, we reﬁned our method by conducting one Gamma
regression model for all episodes across all ETG types, which
enabled us to estimate physicians’ relative performance more
consistently and efﬁciently based on the inclusion of physician-
speciﬁc intercepts. Regression models controlled for patient
demographic, health status, and disease severity characteristics
as well as physician quality score to control for the marginal
cost incurred for the provision of evidence-based care (i.e.,
tests, screenings). The weighted kappa score was calculated to
assess agreement between the two approaches. RESULTS: The
weighted kappa between physician rankings from the intercept
model and SCD approach was 0.90, suggesting that the two
methods generated similar physician practice efﬁciency scores.
Physician quality played a signiﬁcant role across all specialties
(higher quality was associated with 12% higher cost, p-
value < 0.0001), but differed with regard to certain specialties
(higher quality was associated with 15% lower costs for internal
medicine, p-value = 0.003), which could have been indicative of
downstream costs that were avoided due to improved quality of
care. CONCLUSION: A regression approach with physician-
speciﬁc intercepts that controls for a comprehensive set of patient
factors and physician quality score produces more consistent and
efﬁcient estimates of physician cost and is more congruent with
the goals of quality measurement.
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OBJECTIVES: Computer Adaptive Testing (CAT) are assessment
instruments based on the Item Response Theory. CAT use a
reduced number of questions (selected from a calibrate item-
bank) in evaluating the subject with a minimum error. These are
characteristics which would be very useful in the Health-Related
Quality of Life-HRQoL area. The purpose of the present work
was to develop a calibrated bank of HRQoL items to used it in
the to construction of a CAT for evaluating the generic HRQoL
in our country: the CAT-Health. METHODS: HRQoL was con-
sidered as an unidimensional construct. An expert panel con-
structed the item bank with items from validated HRQoL
questionnaires and original ones, all with a likert scale of ﬁve
alternatives. A pilot group was interviewed with all these items to
evaluate parameters of Classic and Item Response Theories and
select the anchoring items. A normative group answered part of
the items (through a computer application or in paper) and items
were re-calibrated (using Samejima’s Graded Response Model-
GRM) and norms of item selection were designed. Various simu-
lation studies were carried-out with the ﬁnal calibrated bank of
HRQoL items. RESULTS: Experts panel constructed a bank of
140 HRQoL items. Pilot group (N = 185) answered all the items:
12 items were eliminated because homogeneity coefﬁcient was
under 0.20; Cronbach’s alpha was 0.99; factorial analysis con-
ﬁrmed the uni-dimensionality of the item bank; IRT showed that
23 items had a “b” parameter which did not ﬁt the model
(eliminated). Normative group (N = 1.373) answered 10 differ-
ent questionnaires (5 anchoring items and 10 different) con-
structed with the 105 items remaining in the bank: Information
function indicated that 9 items must be eliminated; GRM was
applied to re-calibrate the items. Finally, norms of item selection
were designed and simulations were carried-out. CONCLU-
SION: A new CAT to evaluate generic HRQoL has been devel-
oped and tested through simulation techniques.
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OBJECTIVES: This study examined patent’s satisfaction
with their physician. Patient satisfaction is a quality measure
that affects treatment outcomes. More speciﬁcally it examines
how perceived patients’ perceptions of empathy from a physician
affect patient satisfaction. METHODS: A cross-sectional
Internet-based survey completed by patients visiting primary care
physician ofﬁces resulted in a convenience sample of 20,901
patient respondents who rated their recent visit to a physician
through a web-based survey. The survey included questions
based on aspects of overall satisfaction with the physician care
and ofﬁce practice and more detailed items including demograph-
ics such as “friendliness”, empathy and time spent with doctor as
well as areas that could be improved. These scales were then used
to represent patient satisfaction. How “friendliness and caring”
the physician was perceived to be was used as a measure of
perceived empathy. RESULTS: Of the 20,901 patients surveyed
from the online survey perceived empathy was the most strongly
predominant correlate associated with patient satisfaction with
their physician was that of empathy with a partial correlation of
0.87 (p < 0.001) and a Pearson correlation of 0.92 (p < 0.001).
Patient satisfaction with the ofﬁce setting was also highly corre-
lated with empathy scores with a partial correlation of 0.72
(p < 0.001) and a Pearson correlation of 0.83 (p < 0.001). Other
factors such as waiting time and problems with appointments,
staff, records, parking doctor care, and ways of obtaining infor-
mation also played a role in how the patients’ perceived their
overall satisfaction with the physician. CONCLUSION: The
patient satisfaction ratings are strongly correlated to patient per-
ception of empathy.
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OBJECTIVES: To identify and describe differences in demo-
graphics, quality of life, resource utilization, and health status
between those with and without private health insurance in the
UK. METHODS: Data for this analysis were obtained from the
2006 National Health and Wellness Survey (NHWS), an annual
nationally representative Internet-based study of the health
status, health care attitudes, behaviors, and outcomes of adults
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(age 18+). The current analysis was limited to respondents from
the UK. Individuals who reported having private health insur-
ance were 1:1 matched with those who did not on age, gender
and highest education level attained (college graduate vs. no
college). Paired t-tests were conducted to assess if any differences
existed for continuous variables. For dichotomous variables,
odds ratios were calculated to determine the likelihood of an
individual with health insurance experiencing comorbidities
compared to those without health insurance, and signiﬁcant dif-
ferences were tested using McNemar’s chi-square. RESULTS: Of
the 1944 respondents with private health insurance, 1925 were
matched to controls without health insurance yielding a 99%
match. Cases were generally healthier than controls. Cases had
higher SF-8 physical summary scores (49.73 vs 47.79, p < 0.001)
and SF-8 mental summary scores (49.72 vs 48.39, p < 0.001)
than controls. Cases had a signiﬁcantly decreased likelihood of
experiencing angina, COPD, heart attacks, over-active bladder,
abdominal bloating, anxiety, emphysema, depression, general-
ized anxiety disorder, pain, panic disorder and social anxiety
disorder. Cases experienced less activity impairment than con-
trols as measured by the Work Productivity and Activity Impair-
ment (WPAI) Questionnaire (19.18% vs. 25.12%, p < 0.001).
However, no signiﬁcant differences were noted for resource
utilization between those with and without private health insur-
ance. CONCLUSION: Unique characteristics differentiate those
with and without private health insurance in the UK. These
differences have ramiﬁcations for health policy and health care
spending.
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OBJECTIVES: To demonstrate that in European pricing and
reimbursement the beneﬁts of the pharmaceutical industries can
be optimised. METHODS: We have examined the reimburse-
ment criteria and drug price establishments of 12 European
countries: UK, The Netherlands, Germany, Sweden, Norway,
Belgium, Italy, Spain, France, Austria, Denmark and Switzerland.
Reimbursement systems were compared across six key reim-
bursement criteria (clinical efﬁcacy, cost effectiveness, budget
impact, foreign price reference, public medical need, value of
treatment) and classiﬁed into three categories whether a Cost
Effectiveness Analysis (CEA) is mandatory, optional or absent. In
parallel, two types of pricing system were identiﬁed: no pricing
reference and reference pricing. We have developed a network
model to demonstrate the relative monetary beneﬁts resulting
from the pricing and reimbursement systems behaviour.
RESULTS: We found that majority of countries determine drug
price before the reimbursement decision in order to perform a
CEA. However in other countries where CEA are optional or
absent, reimbursement decisions generally precede price negotia-
tions. The most important aspect of pricing for all countries
except Germany and UK is the price in other reference countries
(e.g. the price in France is the average of Spain, Italy, Germany
and UK drug prices). Therefore a higher price obtained in Spain
could increase the French drug price. Other countries (like
Belgium or Italy) set price according to speciﬁc country. Prag-
matically each country has its own ﬁxed budget allocated to
different diseases; therefore a reimbursement and price determi-
nation across Europe should be approached strategically to opti-
mise margins and beneﬁts. CONCLUSION: The applications of
CEA for decision making have progressed in European countries
constraining prices and costs to effectiveness. Nevertheless, in
other countries drug prices are more sensitive to public health
and are negotiated with public authorities. A European national
pricing and reimbursement approach by disease network model
could generate optimal monetary beneﬁt for the pharmaceutical
industry.
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OBJECTIVES: The purpose of the study was to compare and
contrast reference pricing with health technology assessment
(HTA) as alternative strategies for obtaining value for money
from pharmaceuticals. METHODS: The study focussed on
decisions about the initial price and reimbursement status of
innovative drugs. Four countries were studied: Germany, The
Netherlands, Sweden and the UK. These countries have operated
one, or both, of the two policies at certain points in time,
sometimes in parallel. Drugs in four groups were considered:
cholesterol-lowering agents, insulin analogues, biologics for
rheumatoid arthritis and atypicals for schizophrenia. RESULTS:
Where reference pricing schemes were in operation, all the drugs
obtained reimbursement. In addition, all the drugs in the same
group were placed in the same cluster. Prices were also similar,
with the exception of cholesterol-lowering agents, where some
generic agents were available. Where technology assessments had
been performed, the use of some drugs (e.g. insulin analogues)
was restricted more than the licensed indication. On occasions,
technology assessments were used to assess whether a premium
price was justiﬁed for a given product. CONCLUSION: Com-
pared with HTA, reference pricing is a relatively blunt instrument
for obtaining value for money from pharmaceuticals. It may have
a role alongside HTA, in making reimbursement decisions about
those drugs which, because of resource constraints, cannot be
subjected to a technology assessment.
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OBJECTIVES: The new Single Technology Appraisal (STA)
process introduced by NICE attempts to shorten the process of
assessment. The purpose of this study was to review, summarise
and critique all of the STAs published to date and to analyse
themes and trends. METHODS: A database was developed to
collate key data from the STAs completed to date with an initial
focus on oncology submissions. Clinical and economic data as
well as summaries of all key comments were extracted from the
manufacturer submission, evidence review group report, expert
submission and the ﬁnal appraisal determination. Data were then
analysed for associations between ICER values, clinical and eco-
nomic evidence and submission outcome. RESULTS: Since the
introduction of the STA process, six STAs have been completed
for drugs in oncology. A further 27 STAs are in development,
with 10 more in oncology. Three out of the six oncology sub-
missions were considered to have resulted in positive guidance
from NICE, recommending the use of the drug in the NHS.
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